

Date: November 10, 2025

Ref. No.: KDL/SE/076/2025-26

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	---

Dear Sir/Madam,

**Sub: Submission of revised Investor Presentation.**

This is with reference to our submission dated November 07, 2025, where we submitted the Investor Presentation for quarter and half year ended September 30, 2025.

In this context, it has come to our notice that there were some typographical errors on slide no. 13 containing “Presence- PAN India” of the uploaded Presentation.

Accordingly, we are enclosing herewith the revised presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025. The above error was unintentional, and we regret the inconvenience caused.

Request you to take the same on your records.

Thanking you,  
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose  
Company Secretary & Compliance Officer  
Encl: as above



# Q2 FY2026 Result Presentation

One of INDIA'S LARGEST Integrated  
Diagnostic Service Provider



# Disclaimer

This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances.



# Krsnaa Diagnostics Limited

---





## Krsnaa Diagnostics At a Glance

186

CT/ MRI Centres

3,500+

Patient Collectionn  
Centres

75

Million+

Patients Served  
Since Inception

120

Pathology Labs

18

States/UT

Presence in India



Krsnaa Diagnostics is one of the **fastest growing and Integrated diagnostic service provider** which includes radiology, pathology and tele-radiology



Provides **quality** and inclusive diagnostic services at **affordable rates** across various segments with a focus on Public Private Partnership model




One of India's largest NABH accredited **tele-radiology reporting hub** with inherent capability & capacity to process X-rays, CT scans and MRI scans, serving patients at remotest locations




The workforce comprises **350+ radiologists, 120+ pathologists, and 3,000+ qualified professionals**, including clinicians, technicians and operators

# Retail Dynamics


Retail Revenue (mn)




Retail Revenue Contribution to Group Revenue



No. of Touch Points



Segment Retail Revenue Mix



**“Q-o-Q Retail Business Revenue Increased By 60%”**

# Q2 FY26 Financial Performance



**Achieved All-Time High Quarterly PAT of INR 239 Mn, Rising 22% Y-o-Y on Strengthening Margins and Operating Leverage**

Particulars	Q2 FY26	Q2 FY25	Growth
Revenue	2,060	1,863	11%
EBIDTA	602	509	18%
EBIDTA Margin	29%	27%	221 bps
PAT	239	196	22%
PAT Margin	12%	11%	111bps


Particulars	Q2 FY26	Q2 FY25	Growth
EPS	7.3	5.9	24%
No. of Patient Served	5.4	5.2	4%
No. of Test performed	16.4	17.1	(4%)
NABL Accreditation (Pathology lab)	57	37	54%
NABH Accreditation (Radiology Centre)	36	24	50%

INR in mn except EPS, NABL & NABH


# Q2 FY26 – Centre Growth

Radiology


CT Centre



MRI Centre



Tele- Radiology Centre




“


Upon completion of our existing order book, we will have **200+ CT/MRI** centres, cementing our position as one of **Asia's Largest Radiology Players.**

Pathology


Reference Lab



Satellite Lab



Collection Centres



“

The Rajasthan project will grow our network to **7** Reference Labs, **41** Mother Labs, **249** Satellite Labs & **5,000+** Collection Centres — making us **India's Deeply Rooted** and **Widely Accessible** Pathology Service Provider.





# Competitive Advantages

# Driving Excellence Through Quality



**American College  
of Radiology™**

India's 1st ACR Accredited  
Company



India's 1st CAP Accredited Lab  
at Government Facility



India's 1st NABH Accredited  
Tele-Radiology Hub

## Service Excellence **Pioneers of Indian Diagnostic Industry**

# Driving Excellence Through Quality

57



National Accreditation Board of  
Testing & Calibration Laboratories

36



National Accreditation Board for  
Hospitals & Healthcare Providers

We are committed to delivering superior quality as our benchmark and proudly served  
**~5.4 mn patients** in Q2 FY26, driven by our continuous focus on excellence.

# Our Strengths

The only listed company in PPP (Public Private Partnership) space with bid win ratio of 75%+

**18 states and union territories** with penetration till tier-II and tier-III towns

**~75 Mn+ patients** served since inception

Integrated diagnostic services available for 24/7 and 365 days, Radiology, Pathology, and Teleradiology

Quality diagnostic services at most affordable prices (~70% lower than the peers)

Operationalizing retail presence in 4 states

Krsnaa has redefined what's possible in diagnostics — proving that we can deliver radiology services at prices up to 70% lower than market, in a **capital-intensive business, and still generate margins** on par with the industry's best. **This isn't a low-price government contract story — it's a high-efficiency, high-impact model built to scale.**



# Our Pricing - “Everyone Can Afford”

Segment	Test	Competition 1	Competition 2	Competition 3	Krsnaa	% lower from competitors
Radiology	CT Brain	4,500	4,500	3,500	880	(75)%
Radiology	MRI Brain	8,000	8,250	7,000	1,340	(81)%
Pathology	CBC	250	250	200	37	(82)%
Pathology	Blood Sugar	85	80	70	20	(71)%
Pathology	Thyroid	500	550	550	55	(90)%
Pathology	Vitamin D	1,500	1,250	1,450	153	(89)%
Pathology	Vitamin B12	1,000	1,100	1,300	69	(95)%
Pathology	HbA1C	550	440	400	49	(88)%

By offering services at **over 70% below** market rates, Krsnaa Diagnostics is expanding access to millions across India — and still growing faster than the industry, proving that **scale, efficiency, and impact can go hand in hand.**

Note:


Amounts are in INR.

Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information




# Presence - PAN India

## Well Diversified Regional Revenue Mix



■ West ■ South ■ North ■ East



India map for representation only, not to scale



# New Centres

---

# State-Of-Art Infrastructure **Enabling Reliable Diagnostics**

## ***Soon to be operationalized AI-Enabled MRI Centres***



**Amravati, Maharashtra**



**Buldhana, Maharashtra**

*Actual centre images*



# State-Of-Art Infrastructure Enabling Reliable Diagnostics

## Soon to be Operationalized Low Radiation CT Scan Centres



**Ranchi, Jharkhand**



**Tuljapur, Maharashtra**

Actual centre images



# Financial Performance



# Consolidated Financial Performance

Particulars	Q2 FY 26		Q2 FY 25		Q1 FY 26		H1 FY 26		H1 FY 25	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	2,060		1,863		1,930		3,990		3,566	
Expenses										
Cost of Material Consumed	481	23%	449	24%	474	25%	955	24%	878	25%
Employee benefits expense	348	17%	339	18%	350	18%	698	18%	660	19%
Fees to hospitals and others	170	8%	174	9%	154	8%	324	8%	297	8%
Other expenses	459	22%	392	22%	428	22%	887	22%	780	22%
Total Expenses	1,458	71%	1,354	73%	1,406	73%	2,864	72%	2,615	73%
EBITDA Before CSR & ESOP	602	29%	509	27%	524	27%	1,126	28%	951	27%
CSR and ESOP	10	1%	15	1%	10	1%	20	1%	30	1%
EBITDA	592	29%	494	26%	514	27%	1,106	28%	921	26%
Less: Finance costs	82	4%	64	3%	63	3%	145	4%	117	3%
Less: Depreciation	236	11%	222	12%	216	11%	452	11%	437	12%
Add: Other income	42	2%	46	2%	40	2%	82	2%	119	3%
PBT	316	15%	254	14%	275	14%	591	15%	486	14%
Tax	77	4%	58	3%	69	4%	146	4%	111	3%
PAT	239	12%	196	11%	205	11%	445	11%	375	11%

In mn

# Consolidated Financial Performance

## Assets

Sep 30, 2025 Mar 31, 2025

### Non-current assets

Property, plant and equipment	6,800.17	6,674.34
Capital work-in-progress	302.05	29.63
Intangible assets	26.65	29.49

### Financial assets

Investments	315.61	315.42
Other financial assets	719.94	1,182.77
Deferred tax asset (net)	34.58	33.33
Other non-current assets	1,101.39	406.25
<b>Total non-current assets</b>	<b>9,300.39</b>	<b>8,671.23</b>

### Current assets

Inventories	314.89	294.76
-------------	--------	--------

### Financial assets

Trade receivables	3,582.79	2,777.45
Cash and cash equivalents	105.60	38.46
Bank balances other than cash and cash equivalent	1,193.65	645.90
Other financial assets	297.82	282.89
Other current assets	271.77	105.26

<b>Total current assets</b>	<b>5,766.52</b>	<b>4,144.72</b>
-----------------------------	-----------------	-----------------

<b>Total Assets</b>	<b>15,066.91</b>	<b>12,815.95</b>
---------------------	------------------	------------------

## Liabilities

Sep 30, 2025 Mar 31, 2025

### Equity

Equity share capital	162.19	161.45
Other equity	9,067.36	8,666.25
<b>Total equity</b>	<b>9,229.55</b>	<b>8,827.70</b>

### Liabilities

#### Non-current liabilities

Borrowings	538.00	185.04
Lease Liabilities	350.96	286.52
Other financial liabilities	583.43	208.29
Employee benefit obligations	35.53	28.61
Deferred Tax Liabilities	254.81	225.91
Other non-current liabilities	-	-

<b>Total non-current liabilities</b>	<b>1,762.73</b>	<b>934.37</b>
--------------------------------------	-----------------	---------------

### Current liabilities

#### Financial liabilities

Borrowings	1,846.76	1470.38
Lease Liabilities	121.68	93.33
Trade payables	1,396.46	971.27
Other financial liabilities	505.76	371.14
Other current liabilities	59.83	54.17
Provision	63.72	55.77
Current Tax Liabilities (net)	80.42	37.82

<b>Current liabilities</b>	<b>4,074.63</b>	<b>3,053.88</b>
----------------------------	-----------------	-----------------

<b>Total Liabilities</b>	<b>5,837.36</b>	<b>3,988.25</b>
--------------------------	-----------------	-----------------

<b>Total Equity and Liabilities</b>	<b>15,066.91</b>	<b>12,815.95</b>
-------------------------------------	------------------	------------------



For further information please contact

## Krsnaa Diagnostics

**Vivek Jain, Head- Investor Relations**



[head.investor@krsnaa.in](mailto:head.investor@krsnaa.in)



[Contact: +91 74107 00645](tel:+917410700645)



<https://krsnaadiagnostics.com>